Researchers for Anthos and clinical partners recently published and presented final positive Phase II data for its anticoagulant candidate, the fully human monoclonal antibody abelacimab, from the ANT-005 trial (EudraCT number 2019-003756-37), which evaluated 412 patients undergoing elective total knee arthroplasty. A single dose of abelacimab administered after elective total knee arthroplasty reduced the rate of venous thromboembolism (VTE) by ~80% compared to Lovenox® (enoxaparin), a low molecular weight heparin marketed by Sanofi . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge